Company
Intra-Cellular
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
1
1 still marketed
Novel approvals
1
Approvals since 2021
4
Originals and new uses
Phase 3 trials
21
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- A Study to Asses Safety and Tolerability of ITI-1284 Given Alone or as an Additional Treatment in Participants With Generalized Anxiety Disorder (GAD)Pivotal-lookingRecruiting
Intra-Cellular Therapies, Inc.Industry
NCT07807865 · 900 participants (planned) · Start Sep 3, 2026 · Primary completion Feb 18, 2030
Drug: ITI-1284 · For: Generalized Anxiety Disorder
Sites: Los Angeles, California; Miami, Florida; Brooklyn, New York
- A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD TreatmentPivotal-lookingRecruiting
Intra-Cellular Therapies, Inc.Industry
NCT07856420 · 705 participants (planned) · Start Sep 29, 2026 · Primary completion Sep 20, 2030
Drug: JNJ-99245354; Placebo · For: Generalized Anxiety Disorder
Sites: Temecula, California; Miami, Florida; Springfield, Massachusetts · 4 sites in all
- Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderPivotal-lookingRecruiting
Intra-Cellular Therapies, Inc.Industry
NCT05850689 · 470 participants (planned) · Start May 2, 2023 · Primary completion Apr 5, 2027
Drug: Lumateperone; Placebo · For: Major Depressive Disorder
Sites: Huntsville, Alabama; Pico Rivera, California; Farmington, Connecticut · 69 sites in all
- Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric PatientsPivotal-lookingRecruiting
Intra-Cellular Therapies, Inc.Industry
NCT06372964 · 384 participants (planned) · Start May 14, 2024 · Primary completion Oct 31, 2031
Drug: Lumateperone; Placebo · For: Bipolar Depression
Sites: Dothan, Alabama; Little Rock, Arkansas; Anaheim, California · 68 sites in all
- Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum DisorderPivotal-lookingRecruiting
Intra-Cellular Therapies, Inc.Industry
NCT06229210 · 300 participants (planned) · Start Jan 25, 2024 · Primary completion Apr 28, 2032
Drug: Lumateperone · For: Schizophrenia; Bipolar Disorder; Autism Spectrum Disorder
Sites: Phoenix, Arizona; Little Rock, Arkansas; Anaheim, California · 65 sites in all
- Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric PatientsPivotal-lookingRecruiting
Intra-Cellular Therapies, Inc.Industry
NCT06690398 · 160 participants (planned) · Start Nov 22, 2024 · Primary completion Jun 21, 2027
Drug: Lumateperone high dose; Lumateperone low dose and 1 more · For: Irritability Associated With Autism Spectrum Disorder
Sites: Dothan, Alabama; Phoenix, Arizona; Anaheim, California · 39 sites in all
- Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric PatientsPivotal-lookingRecruiting
Intra-Cellular Therapies, Inc.Industry
NCT06706674 · 160 participants (planned) · Start Dec 6, 2024 · Primary completion Jun 21, 2027
Drug: Lumateperone high dose; Lumateperone low dose and 1 more · For: Irritability Associated With Autism Spectrum Disorder
Sites: Little Rock, Arkansas; Sacramento, California; Sherman Oaks, California · 41 sites in all
Marketed drugs (1)
Newest FDA action first.
- Caplyta Lumateperone Tosylate · 2019
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.